摘要
异基因造血干细胞移植（allo—HSCT）为可能治愈国际预后积分系统（IPSS）中、高危骨髓增生异常综合征（MDS）患者的方法。然而，MDS患者多为中、老年人，难以耐受清髓性异基因造血干细胞移植（MAC-HSCT）。减低剂量预处理异基因造血干细胞移植（RIC-HSCT）具有低毒、高效等特点，被广泛应用于MDS的治疗。目前，常用的预处理方案为氟达拉滨联合烷化剂，但各种预处理方案的疗效差异较大。RIC—HSCT对IPSS中、高危老年MDS患者有其独特优势，但不同移植类型、allo—HSCT前肿瘤负荷、IPSS危险度分层及移植前合并症对RIC—HSCT疗效的影响尚无定论。笔者拟就近年来RIC—HSCT应用于MDS治疗的研究进展进行综述。
Allogeneic hematopoietic stem cell transplantation（allo-HSCT） is likely to be the optimum method to cure international prognostic scoring system （IPSS） intermediate and high-risk patients with myelodysplastic syndrome（MDS）. However, patients suffered with MDS are usually too old to undergo myeloablative conditioning allogeneic stem cell transplantation（MAC-HSCT）. On account of its advantages of higher efficiency and lower toxicity, reduced intensity conditioning allogeneic stem cell transplantation （RIC-HSCT） is widely applied in the treatment of MDS patients. Currently, fludarabine plus alkylating regimens are widely applied, but the clinical outcomes are different from each regimen. Although RIC- HSCT has unique advantages in treating intermediate and high-risk elder MDS compared with MAC-HSCT and non-HSCT therapy, whether the outcome is influenced by factors such as tumor burden, recipient age, IPSS risk stratification, type of allo-HSCT, and comorbidity before transplantation is still unclear. In this article, we review literatures on RIC-HSCT in treatment of MDS.
出处
《国际输血及血液学杂志》
CAS
2016年第2期143-148,共6页
International Journal of Blood Transfusion and Hematology
基金
新疆维吾尔自治区高新技术项目（201317104）
关键词
骨髓增生异常综合征
移植预处理
造血干细胞移植
Myelodysplastic syndrome
Transplantation conditioning
Hematopoietic stem cell transplantation
